欢迎登录材料期刊网

材料期刊网

高级检索

目前恶性肿瘤已成为人类因疾病死亡的主要因素. 化疗是当前肿瘤治疗的主要方式之一,然而常用的化疗药物存在诸多缺陷,如副作用大、易产生耐药性、难以监测等. 开发高效低毒治疗药物是当前肿瘤治疗的研究热点之一. 通过特定的纳米药物载体可提升药物在病变区域的有效浓度,提高杀伤肿瘤细胞效率,降低抗肿瘤药物毒副作用. 苝酰亚胺衍生物(perylenediimides derivatives,PDI)是一种稳定性高、荧光效率优异的纳米分子材料,且易修饰,可连接特定基团,增强其生物兼容性并行使多种功能,可作为药物载体、抗肿瘤药物、荧光示踪剂等用于肿瘤诊断和治疗. 本文综述PDI在药物载体、肿瘤细胞抑制剂和荧光示踪剂三方面的研究进展. 为PDI应用于临床总结理论研究成果,并进一步指导其实际应用工作的开展.

At present, malignant tumor has been becoming the main threat to human's death.Chemotherapy is one of the main methods of tumor therapy.However, there are many defects, such as side effects, drug resistance and difficulty of monitoring.Most of research works focus on improving the drugs' therapeutic effect and cutting down it's side effects, drugs' carriers are used to increase its concentration in the local lesions, which promote the efficiency of inhibiting tumor cells and reduce side effects with antitumor drugs.Perylenediimides derivatives(PDI) is a highly stable fluorescing materials, which is easily modified to enhance its biocompatibility and exercise a variety of functions.It can be used as drug carriers, fluorescence imaging, and anticancer drugs for cancers' diagnosis and treatment.This review focuses on the recent progress of PDI's biomedical applications and elaborates from drug carrier, antitumor drugs and fluorescent tracer aspects.This review summarized the basic experimental theory and gave the way for the application of PDI in clinical work.

参考文献

上一张 下一张
上一张 下一张
计量
  • 下载量()
  • 访问量()
文章评分
  • 您的评分:
  • 1
    0%
  • 2
    0%
  • 3
    0%
  • 4
    0%
  • 5
    0%